Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
| Revenue (TTM) | $1.12M |
| Gross Profit (TTM) | $-55.24M |
| EBITDA | $-83.24M |
| Operating Margin | -10396.00% |
| Return on Equity | -52.70% |
| Return on Assets | -23.30% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $4.02 |
| Price-to-Book | 3.51 |
| Price-to-Sales (TTM) | 736.70 |
| EV/Revenue | - |
| EV/EBITDA | -3.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -26.70% |
| Shares Outstanding | $60.39M |
| Float | $52.13M |
| % Insiders | 3.51% |
| % Institutions | 38.53% |
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference.
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or "the Company") (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
ZUG, Switzerland, June 10, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
